Labiana Health S.A. (LAB) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Labiana Health S.A. €5.36, price €6.00, upside -10.7%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Labiana Health S.A. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
51‑month range €1.08 – €7.55 · fair‑value band €3.75 – €6.97 · the €6.00 price screens above the €5.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Labiana Health in your weekly email
Every Wednesday you see whether Labiana Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products.
Show more
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms, bacterial vaccines and biological formats; and Fosfomycin trometamol under the Fosfomicina Labiana brand name. In addition, the company offers contract developments, quality system and manufacturing services. Labiana Health S.A. was founded in 1958 and is based in Pozuelo de Alarcón, Spain.
Stock analysis
Labiana Health S.A. (LAB) currently trades at €6.00, while our model-based Fair Value estimate is €5.36, implying the stock looks roughly 11.9% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €7.69 per share, and 6 of the 15 models we run sit above the €6.00 price.
Bear case: the Earnings-Based group reads lowest at €3.01, and 9 of the 15 models stay below the price. Evidence for this calculation is medium.
Scenario range: €3.75 (bear) to €6.97 (bull), the price of €6.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Labiana Health S.A. reported revenue of €75.2M in FY2025 versus €57.0M in FY2021, a compound +7.2%/yr. Reported net income was €2.6M in FY2025.
Key figures
Market cap €56.9M · P/E ratio 16.7 · P/S ratio 0.57 · EPS (TTM) €0.3600 · Net margin 3.4% · Return on equity 69.7% · Return on assets (EBIT) 2.0% · Operating margin 5.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 83% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −11%, LAB screens richer than that median.
Fair Value models
Bear €3.75Fair Value €5.36Bull €6.97
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.2633 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+13.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.3% (2020) → 9.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 614 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−11% · Above median
Profitability
Return on equity (TTM)70% · Top 25%
Return on assets8% · Top 25%
Net margin (TTM)3% · Below median
Operating margin (TTM)6% · Below median
Growth and dividend
Revenue growth15% · Above median
Balance sheet
Debt / equity5.86× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)16.7× · Cheaper than median
P/B12.73× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Labiana Health S.A. Fair Value". https://www.fairvalue-calculator.com/stock/LAB.MC
Frequently asked questions
Is Labiana Health S.A. (LAB) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €5.36 versus a price of €6.00, about −11% upside (overvalued).
What is the fair value of LAB?
Our model-based fair value for Labiana Health S.A. is €5.36 (as of Sep 23, 2026), built from audited fundamentals. The current price: €6.00.
What is the quality score of LAB?
Labiana Health S.A. has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Labiana Health S.A. (LAB)?
Our model-based price target is the fair value of €5.36 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario €3.75, optimistic scenario €6.97. It is a calculation from audited fundamentals, not an analyst target.
What is the Labiana Health S.A. stock forecast for 2026?
Our models put fair value at €5.36, about −11% upside versus a price of €6.00 (overvalued). Cautious scenario €3.75, optimistic scenario €6.97. The calculation is refreshed regularly with new filings.
What is the revenue of Labiana Health S.A. (LAB)?
Labiana Health S.A. reported trailing-twelve-month revenue of about €71.7M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Labiana Health S.A. (LAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Labiana Health S.A. it is €5.36 per share (as of Sep 23, 2026), against a price of €6.00. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Labiana Health S.A. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, LAB trades above its calculated fair value: price €6.00, fair value €5.36, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LAB?
No. The price is what the market pays today (€6.00); the fair value is what the company's own numbers justify (€5.36). For Labiana Health S.A. the two are €0.6400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Labiana Health S.A. worth?
The market values Labiana Health S.A. at about €56.9M (market capitalisation, as of Sep 23, 2026). Per share that is €6.00; our models calculate a fair value of €5.36 per share.
What do the bullish and bearish scenarios say about LAB?
Our models span a range for Labiana Health S.A.: cautious scenario €3.75, base €5.36, optimistic €6.97 per share (as of Sep 23, 2026, price €6.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LAB?
Labiana Health S.A. trades at a price-to-earnings ratio of 16.7 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €5.36 is built from several models across several years. Other multiples: PEG 0.2, P/B 12.7, P/S 0.8, EV/EBITDA 8.0.
What is the PEG ratio of LAB?
The PEG ratio of Labiana Health S.A. is 0.16 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Labiana Health S.A. (LAB)?
Balance-sheet figures for Labiana Health S.A. (as of Sep 23, 2026): return on equity 69.7%, debt of 5.86 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is LAB from its 52-week high?
Labiana Health S.A. trades at €6.00, about 27% below its 52-week high of €8.20 and 83% above the low of €3.28 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of €5.36 is for.
Which stocks are comparable to Labiana Health S.A.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Labiana Health S.A. stock attractive at the current price?
The data as of Sep 23, 2026: price €6.00, calculated fair value €5.36 (−11%), Quality Score 59/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LAB calculated?
We run Labiana Health S.A. through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €5.36, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Labiana Health S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Labiana Health S.A. (LAB)?
The closing price on Sep 22, 2026 was €6.00. Our model-based fair value is €5.36, about −11% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Labiana Health S.A. right now?
A fairly wide model range (€3.75 to €6.97) leaves room in how you read the outcome. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Labiana Health S.A.
How large is the market capitalisation of Labiana Health S.A. (LAB)?
The market capitalisation of Labiana Health S.A. is €56.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Labiana Health S.A. (LAB)?
The price-to-sales ratio of Labiana Health S.A. is 0.57 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Labiana Health S.A. (LAB)?
Earnings per share at Labiana Health S.A. are €0.3600 (price ÷ EPS = P/E 16.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Labiana Health S.A. (LAB)?
The net margin of Labiana Health S.A. is 3.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Labiana Health S.A. (LAB)?
The return on equity (ROE) of Labiana Health S.A. is 69.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Labiana Health S.A. (LAB)?
On an EBIT basis the return on assets of Labiana Health S.A. is 2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Labiana Health S.A. (LAB)?
The operating margin of Labiana Health S.A. is 5.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Labiana Health S.A. (LAB)?
Revenue at Labiana Health S.A. is growing +15.0% versus a year earlier (3y avg +9.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Labiana Health S.A. (LAB)?
Earnings per share at Labiana Health S.A. are growing +55.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Labiana Health S.A. (LAB) generate?
The free cash flow of Labiana Health S.A. is −€2.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Labiana Health S.A. (LAB) carry?
The net debt of Labiana Health S.A. is €30.1M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Labiana Health S.A. in the live analysis
One click puts Labiana Health S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
